Research Background: This study aimed to scrutinize the chemotherapy’s effect on estradiol levels in patients with triple-negative breast cancer (TNBC) at low-resource country. Methods: This prospective analytic observational cohort study involved patients with TNBC who had undergone surgery and had never received chemotherapy or hormonal therapy before. Patients were checked for estradiol levels before and after chemotherapy. This study was conducted at the Surgical Oncology Department of Regional Public Hospital Dr. Moewardi, Surakarta Indonesia, from April 2020 to March 2021. Descriptive data were presented in a frequency table based on age, menopausal status, parity status, breastfeeding status, hormonal contraception, hormonal contraception duration, family history, stage, and histological grade. Differences in estradiol changes before and after chemotherapy (mean+sd) were then reported. Results: From a total of 23 patients, 21 patients (91.3%) experienced a decrease in estradiol levels, while two patients (8.7%) underwent an increase in serum estradiol levels after chemotherapy. The mean decrease was 11.57 pg/ml. The two samples that experienced an increase in estradiol levels had a mean increase of 16.5 pg/ml. There was a significant difference between estradiol levels before and after undergoing chemotherapy, with p-value=0.001. Conclusions: In this research, chemotherapy reduced estradiol levels in TNBC patients. Statistically significant reductions in estradiol levels were based on the disease stage.

Background: The novel coronavirus known as SARS-CoV-2 has spread worldwide and caused the COVID-19 pandemic. In September 2020, more than 32 million confirmed cases of COVID-19, with a death toll of more than 990,000. Among COVID-19 patients, those with cancer had worse outcomes than those without malignancy, but in some studies, the mortality rates differed significantly, ranging from 3.7% to 61.5%. Method: In this descriptive study, survival analysis with the Kaplan Meier curve was used to determine the healing rate of patients with cancer exposed to COVID-19 and undergoing treatment at dr. Moewardi General Hospital Surakarta-Indonesia from February to December 2020, and the Log Rank test was used to analyze data on two related groups. Results: The analysis using the Kaplan Meier method, female patients were found to have a higher survival rate than females, paged less than 50 years had a higher survival rate than those aged > 51 years, breast cancer had the lowest survival rate, and comorbidity of anemia had a higher survival rate than those with other comorbidities. The Log Rank test found a significant difference in the cumulative survival rates of cancer patients with COVID-19 with a p-value of 0.010 for comorbidity types. Meanwhile, from gender (p = 0.632), age (p = 0.672), type of cancer (p = 0.472), there was no significant difference. Conclusion: COVID-19 female patients aged less than 50 years with types of malignancy other than breast cancer and comorbidity of anemia have a higher survival rate..